How much is Emalex Biosciences worth in 2026?

Emalex Biosciences has a current valuation of N/A based on their Early Stage VC round and secondary market data.

How much funding has Emalex Biosciences raised?

Emalex Biosciences has raised N/A in total funding across 2 funding rounds.

Emalex Biosciences

Drug Discovery

Emalex Biosciences valuation and funding history | Last updated: October 21, 2022 | 2 funding rounds

Current Valuation

N/A

As of October 21, 2022

Total Funding Raised

N/A

Across 2 rounds

Last Round

Early Stage VC

$250.0M

Last Funding

Oct 2022

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
October 21, 2022	Early Stage VC	$250.0M	N/A	-
February 26, 2021	Early Stage VC	$35.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Emalex Biosciences is currently valued at N/A as of October 21, 2022.

Track Emalex Biosciences Valuation Updates

Get notified when Emalex Biosciences raises new funding or valuation changes

Explore More Data

Detailed analysis for Emalex Biosciences

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Emalex Biosciences's valuation history, funding rounds, and growth metrics.

No credit card required

What is Emalex Biosciences Worth in 2026?

Emalex Biosciences is a leading private company in the Drug Discovery sector. Track Emalex Biosciences's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Emalex Biosciences Valuation is Determined

Private company valuations like Emalex Biosciences's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.